DNA Print Genomics Return on Equity

DNA Print Genomics (DNAG) currently reports a ROE of 54.26%. That is above the Healthcare sector average of 13.26%. Use the charts on this page to explore DNA Print Genomics's ROE history and peer comparisons.

DNA Print Genomics's ROE of 54.26% is higher than the Healthcare sector average of 13.26%. That is roughly 309.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but DNA Print Genomics's current 54.26% should be judged against Healthcare norms (sector average: 13.26%) and against DNAG's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 54.26%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.26%. From there, open related valuation or income-statement pages for DNA Print Genomics, and consider following DNAG for alerts when major investors trade the stock.

DNA Print Genomics is classified in the Healthcare sector. On ROE, it currently shows 54.26% versus a sector average near 13.26%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DNAG with unrelated industries.